Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The value of BCMA-targeting agents in treating patients with penta-refractory multiple myeloma

Shebli Atrash, MD, Levine Cancer Institute, Charlotte, NC, discusses the results of a retrospective study evaluating the outcomes of patients with penta-refractory multiple myeloma treated with BCMA-targeting immunotherapies over standard of care (SOC) approaches. Patients treated with BCMA-based immunotherapy demonstrated an increase in progression-free survival (PFS), highlighting the value of BCMA as a target in this disease. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.